Adapted from news article shared on the University of Liverpool website.
Nidor Diagnostics is working with its industrial partner to carry out final validation of a new diagnostic for irritable bowel syndrome (IBS) before commercial launch.
Nidor is spin-out company between the University of Liverpool, UWE Bristol, the University of Bristol and The Wellcome Trust.
The company was established to develop a medical diagnostic device to improve the diagnosis of bowel disorders. The device, named Inform ™, can detect the volatile organic compounds in patient samples, in order to diagnose and monitor a range of medical conditions.
The company has recently agreed to partner with an accredited clinical laboratory, licensed to undertake trials for regulatory work. In addition, Nidor has received £75,500 funding from the Liverpool City Region Future Innovation Fund to build its first instruments to be trialled and validated by the laboratory. For the first time ever, Nidor Diagnostics will be able to positively diagnose IBS and help patients to get the correct treatment.
IBS has a huge impact on the lives of patients, bringing cramps, severe pain and unpredictable bowel habits. Despite being a common condition, there is currently no test to definitively diagnose the condition, with many doctors instead performing numerous tests to rule out other conditions.
Over-investigation of symptoms related to IBS can also prove costly and potentially dangerous. Patients often perceive that an IBS diagnosis is only made when doctors don’t know what is wrong..
Previous studies from the University of Liverpool’s Professor Chris Probert, co-inventor of the new diagnostic technology, have repeatedly shown that the gas pattern from stool samples can be used to separate patients with IBS from those with healthy bowels as well as those with inflamed bowels.
Ben De Lacy Costello, Associate Professor of Biosensing and Diagnostics at UWE Bristol and UWE co-inventor of the technology said: “Myself and Professor Norman Ratcliffe had an interest in the changes in smell induced by disease processes and making sensor systems to detect these changes. Our long running collaboration the University of Liverpool gave this work a clinical focus and it is great to see commercial diagnostic tests being developed by Nidor on the back of this collaborative research effort”
Nidor is planning to be able to launch its first services in late 2021.
Read the original release here.